Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 4D Molecular Therapeutics, Inc.FDMT · Entity 2419 | See Remarks | March 06, 2025 | March 10, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
4D Molecular Therapeutics, Inc.
Report date March 06, 2025 · Filed March 10, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.14 · Expires 2035-03-05 | Direct | 130,000 |
Reported balance
After 2025-03-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-03-06 · Grant · Acquired 130,000 · Balance 130,000 F1: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BridgeBio Oncology Therapeutics, Inc.
Report date April 01, 2026 · Filed May 05, 2026
Section 16 reporting ended · disclosed 2026-05-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,806 |
Reported balance
After 2026-04-01 transaction · row 1
1 source rowRow 1 · 2026-04-01 · Tax withholding · Disposed 524 · Balance 22,806 F1: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units.
Myovant Sciences Ltd.
Report date March 10, 2023 · Filed March 10, 2023
Section 16 reporting ended · disclosed 2023-03-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-03-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-03-10 · Disposition to issuer · Disposed 20,724 · Balance 181,972 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2: At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"). Row 2 · 2023-03-10 · Disposition to issuer · Disposed 181,972 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F3: Reflects restricted stock units ("RSUs"). Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.83 · Expires 2031-09-14 | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-10 · Disposition to issuer · Disposed 165,192 · Balance 0 F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4: One-fourth of the options vested on September 15, 2022, and one-sixteenth of the options vest each quarter thereafter. |
| Performance Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2023-03-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-10 · Disposition to issuer · Disposed 111,111 · Balance 0 F6: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time. F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). |
Filing footnotes · ownership attribution and instrument terms
F1: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger").
F2: At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration").
F3: Reflects restricted stock units ("RSUs"). Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time.
F4: One-fourth of the options vested on September 15, 2022, and one-sixteenth of the options vest each quarter thereafter.
F5: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option.
F6: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2026 Filed May 5, 2026 23:01 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | Tax withholdingCommon Stock | 524 | $9.03 | $4,731.72 |
DisclosureSEC source: 0001193125-26-207031 · ownership.xml · nonDerivative · entry 1 Mehra Uneek · CIK 0001881504 · Former Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,806 F1 · shares: Represents the number of shares of the Issuer's Common Stock withheld by the Issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:58 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $10.19 | $0.00 |
DisclosureSEC source: 0001193125-26-104384 · ownership.xml · derivative · entry 2 Mehra Uneek · CIK 0001881504 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2036-03-09 F2 · derivative.exercise_date: 1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| March 10, 2026 Filed Mar 12, 2026 20:58 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantCommon Stock | 23,330 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-104384 · ownership.xml · nonDerivative · entry 1 Mehra Uneek · CIK 0001881504 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,330 F1 · shares: Represents a grant of restricted stock units ("RSUs"), each representing a contingent right to receive one share of the Issuer's Common Stock. The RSUs vest in 16 equal quarterly installments over a period of four years from January 1, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date. The RSUs will be settled in shares of Common Stock upon vesting. Read SEC document |
| August 26, 2025 Filed Aug 28, 2025 20:34 UTC | BridgeBio Oncology Therapeutics, Inc. BBOT · Entity 5215 | GrantStock Option (Right to Buy) · Derivative | 633,570 | $0.00 Strike: $9.59 | $0.00 |
DisclosureSEC source: 0000950170-25-111986 · ownership.xml · derivative · entry 1 Mehra Uneek · CIK 0001881504 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 633,570 Underlying: Common Stock · 633,570 shares Expires 2035-08-25 F1 · derivative.exercise_date: 25% of the shares underlying such option shall vest on July 21, 2026, with the remainder vesting in thirty-six substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service the Issuer on each such vesting date. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 23:57 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 130,000 | $0.00 Strike: $4.14 | $0.00 |
DisclosureSEC source: 0000950170-25-036685 · ownership.xml · derivative · entry 1 Mehra Uneek · CIK 0001881504 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 130,000 shares Expires 2035-03-05 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 21:05 UTC | 4D Molecular Therapeutics, Inc. FDMT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $14.42 | $0.00 |
DisclosureSEC source: 0000950170-23-070016 · ownership.xml · derivative · entry 1 Mehra Uneek · CIK 0001881504 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2033-12-10 F1 · derivative.exercise_date: The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of December 11, 2023 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:17 UTC | 4D Molecular Therapeutics, Inc. FMDT · Entity 2419 | GrantStock Option (Right to Buy) · Derivative | 229,634 | $0.00 Strike: $12.73 | $0.00 |
DisclosureSEC source: 0001610717-23-000301 · form4.xml · derivative · entry 1 Mehra Uneek · CIK 0001881504 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 229,634 Underlying: Common Stock · 229,634 shares Expires 2033-09-30 F1 · derivative.exercise_date: The stock option will vest with respect to 25% of the total number of the underlying shares on September 11, 2024, and the remaining shares will vest in equal monthly installments over the following three-year period, such that the stock option will be fully vested on September 11, 2027, subject to the Reporting Person continuing to be a service provider to Issuer through each vesting date. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 14:31 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerPerformance Stock Unit · Derivative | 111,111 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-017721 · doc4.xml · derivative · entry 4 Mehra Uneek · CIK 0001881504 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 111,111 shares Expires not disclosed F6 · derivative.exercise_price: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time. F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F6 · price: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time. F6 · derivative.exercise_date: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time. F6 · derivative.expiration_date: Each performance-based restricted stock unit ("PSU") outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such PSUs (deeming performance goals as being satisfied) immediately prior to the Effective Time. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 14:31 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerStock Options (Right to Buy) · Derivative | 165,192 | Not disclosed Strike: $21.83 | Not disclosed |
DisclosureSEC source: 0001209191-23-017721 · doc4.xml · derivative · entry 3 Mehra Uneek · CIK 0001881504 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 165,192 shares Expires 2031-09-14 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F5 · price: Each then-outstanding and unexercised Issuer stock option (whether vested or unvested) was canceled and converted into the right to receive an amount (subject to any withholding tax) in cash, without interest, equal to the product of (a) the excess, if any, of (i) the Per Share Consideration over (ii) the applicable exercise price for such option, multiplied by (b) the total number of Issuer common shares subject to such option. F4 · derivative.exercise_date: One-fourth of the options vested on September 15, 2022, and one-sixteenth of the options vest each quarter thereafter. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 14:31 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerCommon Shares | 181,972 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-017721 · doc4.xml · nonDerivative · entry 2 Mehra Uneek · CIK 0001881504 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F3 · price: Reflects restricted stock units ("RSUs"). Each RSU outstanding immediately prior to the Effective Time that had not been settled in Issuer common shares was canceled and converted into the right to receive an amount (subject to any applicable withholding tax) in cash, without interest, equal to the product of (a) the Per Share Consideration, multiplied by (b) the total number of Issuer common shares subject to such RSU immediately prior to the Effective Time. Read SEC document |
| March 10, 2023 Filed Mar 10, 2023 14:31 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | Disposition to issuerCommon Shares | 20,724 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-017721 · doc4.xml · nonDerivative · entry 1 Mehra Uneek · CIK 0001881504 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,972 F1 · kind: On March 10, 2023, Sumitovant Biopharma Ltd. ("Sumitovant") acquired all of the common shares of the Issuer not previously held by it pursuant to the terms of an Agreement and Plan of Merger, dated as of October 23, 2022 (the "Merger Agreement"), and a related Statutory Merger Agreement (the "Statutory Merger Agreement", and together with the Merger Agreement, the "Merger Agreements"), entered into by and among the Issuer, Sumitovant, Zeus Sciences Ltd., a wholly owned subsidiary of Sumitovant ("Merger Sub"), and other parties thereto. Pursuant to the Merger Agreements, Merger Sub merged with and into the Issuer, with the Issuer continuing as a wholly owned subsidiary of Sumitovant (the "Merger"). F2 · price: At the effective time of the Merger (the "Effective Time"), each common share of the Issuer outstanding immediately prior to the Effective Time (other than certain excluded shares) automatically converted into the right to receive $27.00 in cash, without interest and less any applicable withholding taxes (the "Per Share Consideration"). Read SEC document |
| December 16, 2022 Filed Dec 21, 2022 01:07 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 2,241 | $26.75 | $59,946.75 |
DisclosureSEC source: 0001209191-22-062257 · doc4.xml · nonDerivative · entry 1 Mehra Uneek · CIK 0001881504 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,696 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. Read SEC document |
| September 16, 2022 Filed Sep 20, 2022 20:56 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | SaleCommon Shares | 9,243 | $18.86 | $174,322.98 |
DisclosureSEC source: 0001209191-22-050745 · doc4.xml · nonDerivative · entry 1 Mehra Uneek · CIK 0001881504 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,937 F1 · shares: Represents the number of shares sold by the reporting person to cover the tax obligation realized upon the vesting of restricted stock units previously reported in Table I. F2 · price: The shares were sold at prices ranging from $18.80 to $18.86. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 15, 2022 Filed Apr 19, 2022 20:52 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 111,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-024788 · doc4.xml · nonDerivative · entry 1 Mehra Uneek · CIK 0001881504 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,180 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the common shares underlying the RSUs vest on April 15, 2023, and 1/16 of the common shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:31 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantStock Options (Right to Buy) · Derivative | 165,192 | $0.00 Strike: $21.83 | $0.00 |
DisclosureSEC source: 0001209191-21-056645 · doc4.xml · derivative · entry 2 Mehra Uneek · CIK 0001881504 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,192 Underlying: Common Shares · 165,192 shares Expires 2031-09-14 F2 · derivative.exercise_date: 1/4 of the Common Shares underlying this option vest on September 15, 2022, and 1/16 of the Common Shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
| September 15, 2021 Filed Sep 17, 2021 20:31 UTC | Myovant Sciences Ltd. MYOV · Entity 115677 | GrantCommon Shares | 103,069 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-056645 · doc4.xml · nonDerivative · entry 1 Mehra Uneek · CIK 0001881504 · Principal Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,069 F1 · shares: The Common Shares are to be acquired upon the vesting of certain Restricted Stock Units ("RSUs") granted to the Reporting Person. 1/4 of the Common Shares underlying the RSUs vest on September 15, 2022, and 1/16 of the Common Shares underlying the RSUs vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.